Awtar Krishan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11495119/publications.pdf

Version: 2024-02-01

75	2,212	201385	233125
papers	citations	27 h-index	45 g-index

87	87	87	2322
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. Cell Cycle, 2014, 13, 2790-2797.	1.3	24
2	Mechanisms of synergism between antagonists of growth hormoneâ€releasing hormone and antagonists of luteinizing hormoneâ€releasing hormone in shrinking experimental benign prostatic hyperplasia. Prostate, 2013, 73, 873-883.	1.2	23
3	Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2617-2622.	3.3	27
4	GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle, 2012, 11, 4203-4210.	1.3	20
5	Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle, 2012, 11, 2518-2525.	1.3	22
6	Flow immunocytochemistry of marker expression in cells from body cavity fluids. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 132-143.	1.1	11
7	ALDH⁺/CD44⁺/CD24^{â^'} expression in cells from body cavity fluids. Cytometry Part B - Clinical Cytometry, 2010, 78B, 176-182.	0.7	1
8	Clickâ€iT Proliferation Assay with Improved DNA Histograms. Current Protocols in Cytometry, 2010, 52, Unit7.36.	3.7	6
9	Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer Letters, 2010, 294, 35-42.	3.2	31
10	GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle, 2009, 8, 3149-3156.	1.3	37
11	Cellular volume and marker expression in human peripheral blood apheresis stem cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 160-167.	1.1	20
12	Application of antiâ€ssDNA monoclonal antibody to study exogenous and apoptosisâ€associated DNA damage. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 1114-1115.	1.1	3
13	Electronic volume of CD34 positive cells from peripheral blood apheresis samples. Cytometry Part B - Clinical Cytometry, 2008, 74B, 182-188.	0.7	11
14	Electronic Cell Volume and ALDH Expression of Hematopoietic Stem Cells Obtained by Apheresis. Blood, 2008, 112, 4132-4132.	0.6	0
15	What links cod liver oil, spinach, and flow cytometry? Flow cytometric detection and quantitation of folic acid receptors in tumor cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2007, 71A, 897-898.	1.1	0
16	The Minimal Instrumentation Requirements for Hoechst Side Population Analysis: Stem Cell Analysis on Low-Cost Flow Cytometry Platforms. Stem Cells, 2006, 24, 2573-2581.	1.4	22
17	Efficacy of 2-halogen substituted d-glucose analogs in blocking glycolysis and killing â€œhypoxic tumor cellsâ€. Cancer Chemotherapy and Pharmacology, 2006, 58, 725-734.	1.1	67
18	Detection of tumor cells in body cavity fluids by flow cytometric and immunocytochemical analysis. Diagnostic Cytopathology, 2006, 34, 528-541.	0.5	20

#	Article	IF	Citations
19	DNA index, genome size, and electronic nuclear volume of vertebrates from the Miami Metro Zoo. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2005, 65A, 26-34.	1.1	30
20	DAPI Fluorescence in Nuclei Isolated from Tumors. Journal of Histochemistry and Cytochemistry, 2005, 53, 1033-1036.	1.3	20
21	Flow Cytometric Monitoring of Fluorescent Drug Retention and Efflux. , 2005, 111, 149-166.		8
22	Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemotherapy and Pharmacology, 2004, 53, 116-122.	1.1	190
23	Androgen and vitamin D receptor expression in archival human breast tumors. Cytometry, 2004, 58B, 53-60.	1.8	1
24	Flow Cytometric Analysis of Electronic Nuclear Volume and DNA Content in Normal Mouse Tissues. Cell Cycle, 2004, 3, 378-381.	1.3	21
25	Flow cytometric analysis of electronic nuclear volume and DNA content in normal mouse tissues. Cell Cycle, 2004, 3, 380-3.	1.3	5
26	Apoptosis enzyme-linked immunosorbent assay distinguishes anticancer drugs from toxic chemicals and predicts drug synergism. Chemico-Biological Interactions, 2003, 145, 89-99.	1.7	16
27	Microplate Screening for Apoptosis with Antibody to Single-Stranded DNA Distinguishes Anticancer Drugs from Toxic Chemicals. Journal of Biomolecular Screening, 2003, 8, 185-190.	2.6	9
28	Apoptosis-based drug screening and detection of selective toxicity to cancer cells. Anti-Cancer Drugs, 2003, 14, 555-561.	0.7	118
29	Flow cytometric monitoring of drug resistance in human tumor cells. , 2003, , 55-60.		0
30	Monitoring of cellular resistance to cancer chemotherapy. Hematology/Oncology Clinics of North America, 2002, 16, 357-372.	0.9	8
31	Androgen receptor expression and DNA content of paraffin-embedded archival human prostate tumors. Cytometry, 2002, 50, 25-30.	1.8	7
32	Identification of Apoptotic Cells by Formamide-induced DNA Denaturation in Condensed Chromatin. Journal of Histochemistry and Cytochemistry, 2001, 49, 369-378.	1.3	158
33	Monitoring of cellular resistance to cancer chemotherapy: Drug retention and efflux. Methods in Cell Biology, 2001, 64, 193-209.	0.5	10
34	NASA/American Cancer Society high-resolution flow cytometry project - II. Effect of pH and DAPI concentration on dual parametric analysis of DNA/DAPI fluorescence and electronic nuclear volume. Cytometry, 2001, 43, 12-15.	1.8	15
35	NASA/American Cancer Society high-resolution flow cytometry project - III. Multiparametric analysis of DNA content and electronic nuclear volume in human solid tumors. Cytometry, 2001, 43, 16-22.	1.8	18
36	NASA/American Cancer Society high-resolution flow cytometry project-I. Cytometry, 2001, 43, 2-11.	1.8	27

#	Article	IF	Citations
37	Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application to rapid drug screening.. Journal of Immunological Methods, 2001, 253, 133-144.	0.6	83
38	Flow cytometric analysis of estrogen receptor expression in isolated nuclei and cells from mammary cancer tissues. , 1999, 36, 131-139.		6
39	Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. , 1999, 38, 118-125.		65
40	Phorbol ester-induced P-glycoprotein phosphorylation and functionality in the HTB-123 human breast cancer cell line. Biochemical Pharmacology, 1998, 56, 709-718.	2.0	14
41	Simultaneous quantitation of plasma doxorubicin and prochlorperazine content by high-performance liquid chromatography. Biomedical Applications, 1997, 703, 217-224.	1.7	34
42	Flow cytometric analysis of P-glycoprotein expression and drug efflux in human soft tissue and bone sarcomas. , 1997, 30, 197-203.		13
43	Drug retention, efflux, and resistance in tumor cells. Cytometry, 1997, 29, 279-285.	1.8	59
44	Flow Cytometric Monitoring of Drug Resistance in Human Solid Tumors. , 1996, , 49-64.		0
45	Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma. Cytometry, 1995, 19, 86-91.	1.8	17
46	Heterogeneity of anthracycline retention and response to efflux blockers in human tumors. Cytometry, 1995, 21, 72-75.	1.8	10
47	Expression of drug resistance-associated mdr-1, GST Ï€, and topoisomerase II genes during cell cycle traverse. Biochemical Pharmacology, 1995, 49, 545-552.	2.0	21
48	Doxorubicin retention and chemoresistance in human mesothelioma cell lines. International Journal of Cancer, 1994, 57, 581-585.	2.3	13
49	Chapter 2 Rapid Determination of Cellular Resistance-Related Drug Efflux in Tumor Cells. Methods in Cell Biology, 1994, 42 Pt B, 21-30.	0.5	2
50	MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients. Cancer Chemotherapy and Pharmacology, 1993, 31, 431-441.	1.1	16
51	Doxorubicin resistance in human melanoma cells: MDR-1 and glutathione S-transferase Ï€ gene expression. Biochemical Pharmacology, 1993, 45, 743-751.	2.0	35
52	Doxorubicin-induced DNA breaks, topoisomerase II activity and gene expression in human melanoma cells. Biochemical Pharmacology, 1993, 45, 1367-1371.	2.0	30
53	Flow cytometric monitoring of glutathione content and anthracycline retention in tumor cells. Cytometry, 1991, 12, 336-342.	1.8	34
54	Comparison of three commercially available antibodies for flow cytometric monitoring of P-glycoprotein expression in tumor cells. Cytometry, 1991, 12, 731-742.	1.8	44

#	Article	IF	Citations
55	Expression of glutathione-related enzymes in human bladder cancer cell lines. Biochemical Pharmacology, 1990, 39, 1817-1820.	2.0	8
56	Anthracycline resistance in murine leukemic P388 CELLS. Biochemical Pharmacology, 1990, 39, 723-728.	2.0	33
57	Cytochrome P450 reductase, antioxidant enzymes and cellular resistance to doxorubicin. Biochemical Pharmacology, 1990, 40, 385-387.	2.0	11
58	Class I MHC Molecules and Doxorubicin Resistant P388 Murine Leukemic Cells. Immunopharmacology and Immunotoxicology, 1989, 11, 583-591.	1.1	0
59	Cellular Resistance to Drugs. Cancer Investigation, 1989, 7, 211-212.	0.6	1
60	Glutathione S-transferases and glutathione peroxidases in doxorubicin-resistant murine leukemic P388 cells. Biochemical Pharmacology, 1989, 38, 3505-3510.	2.0	41
61	Anthracycline-induced DNA breaks and resealing in doxorubicin-resistant murine leukemic P388 cells. Biochemical Pharmacology, 1988, 37, 1763-1772.	2.0	30
62	Patterns of anthracycline retention modulation in human tumor cells. Cytometry, 1987, 8, 306-314.	1.8	65
63	Membraneâ€associated proteins of adriamycin sensitive and resistant murine leukemic P388 cells. International Journal of Peptide and Protein Research, 1986, 27, 414-420.	0.1	7
64	Fine structure of cytochalasin-induced multinucleated cells. Journal of Ultrastructure Research, 1971, 36, 191-204.	1.4	41
65	BINDING OF COLCHICINE-3H TO VINBLASTINE- AND VINCRISTINE-INDUCED CRYSTALS IN MAMMALIAN TISSUE CULTURE CELLS. Journal of Cell Biology, 1971, 48, 407-410.	2.3	43
66	VINBLASTINE-INDUCED RIBOSOMAL COMPLEXES. Journal of Cell Biology, 1971, 49, 927-932.	2.3	25
67	Effect of Some Metabolic Inhibitors on Vinblastine-Induced Ribosomal-Granular Material Complexes. Proceedings Annual Meeting Electron Microscopy Society of America, 1971, 29, 548-549.	0.0	0
68	Ribosome-granular material complexes in human leukemic lymphoblasts exposed to vinblastine sulfate. Journal of Ultrastructure Research, 1970, 31, 272-281.	1.4	58
69	OBSERVATIONS ON THE ASSOCIATION OF HELICAL POLYRIBOSOMES AND FILAMENTS WITH VINCRISTINE-INDUCED CRYSTALS IN EARLE'S L-CELL FIBROBLASTS. Journal of Cell Biology, 1969, 43, 553-563.	2.3	93
70	ASYNCHRONY OF NUCLEAR DEVELOPMENT IN CYTOCHALASIN-INDUCED MULTINUCLEATE CELLS. Journal of Cell Biology, 1969, 43, 618-621.	2.3	36
71	Linear Arrays of Helical Polyribosomes in Cells Exposed to Antitumor Drug Vincristine Sulfate. Proceedings Annual Meeting Electron Microscopy Society of America, 1969, 27, 358-359.	0.0	0
72	Fine structure of the kinetochores in vinblastine sulfate-treated cells. Journal of Ultrastructure Research, 1968, 23, 134-143.	1.4	22

#	Article	IF	Citations
73	HYPERTROPHY OF GRANULAR ENDOPLASMIC RETICULUM AND ANNULATE LAMELLAE IN EARLE'S L CELLS EXPOSED TO VINBLASTINE SULFATE. Journal of Cell Biology, 1968, 39, 211-216.	2.3	59
74	STRUCTURE OF THE MITOTIC SPINDLE IN L STRAIN FIBROBLASTS. Journal of Cell Biology, 1965, 24, 433-444.	2.3	105
75	Ultrastructure of cell division in insect spermatogenesis. Journal of Ultrastructure Research, 1965, 13, 444-458.	1.4	32